CureVac (NASDAQ: CVAC)
CureVac Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CureVac Company Info
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
News & Analysis
Why CureVac Stock Plunged Today
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
Why Shares of CureVac Jumped This Week
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
Why CureVac Stock Leaped 12% Higher Today
The war on cancer advances with the German company's latest clinical development.
Why CureVac's Shares Jumped on Tuesday
The stock rose for the third consecutive day.
Why CureVac Stock Is Sinking Today
Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.
Why CureVac Stock Is Tumbling Today
The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
It isn't likely.
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
CureVac aims to become one of Europe's big suppliers.
Valuation
Earnings Transcripts
CureVac (CVAC) Q1 2022 Earnings Call Transcript
CVAC earnings call for the period ending March 31, 2022.
CureVac (CVAC) Q3 2021 Earnings Call Transcript
CVAC earnings call for the period ending September 30, 2021.
CureVac (CVAC) Q4 2020 Earnings Call Transcript
CVAC earnings call for the period ending March 31, 2021.
CureVac (CVAC) Q3 2020 Earnings Call Transcript
CVAC earnings call for the period ending September 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.